Sitagliptin: Difference between revisions

Sitagliptin
	Adult Indications & Dosage
	Pediatric Indications & Dosage
	Contraindications
	Warnings & Precautions
	Adverse Reactions
	Drug Interactions
	Use in Specific Populations
	Administration & Monitoring
	Overdosage
	Pharmacology
	Clinical Studies
	How Supplied
	Images
	Patient Counseling Information
	Precautions with Alcohol
	Brand Names
	Look-Alike Names

VisualWikitext

Revision as of 18:22, 29 July 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vignesh Ponnusamy, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Sitagliptin is a dipeptidyl peptidase-4 inhibitor that is FDA approved for the {{{indicationType}}} of type 2 diabetes mellitus. Common adverse reactions include hypoglycemia, headache, nasopharyngitis, and upper respiratory infection.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Monotherapy and Combination Therapy for Type 2 Diabetes Mellitus

Dosing Information

The recommended dose of JANUVIA is 100 mg once daily. JANUVIA can be taken with or without food.

Patients with Renal Insufficiency

For patients with mild renal insufficiency (creatinine clearance [CrCl] greater than or equal to 50 mL/min, approximately corresponding to serum creatinine levels of less than or equal to 1.7 mg/dL in men and less than or equal to 1.5 mg/dL in women), no dosage adjustment for JANUVIA is required.
For patients with moderate renal insufficiency (CrCl greater than or equal to 30 to less than 50 mL/min, approximately corresponding to serum creatinine levels of greater than 1.7 to less than or equal to 3.0 mg/dL in men and greater than 1.5 to less than or equal to 2.5 mg/dL in women), the dose of JANUVIA is 50 mg once daily.
For patients with severe renal insufficiency (CrCl less than 30 mL/min, approximately corresponding to serum creatinine levels of greater than 3.0 mg/dL in men and greater than 2.5 mg/dL in women) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of JANUVIA is 25 mg once daily. JANUVIA may be administered without regard to the timing of dialysis.
Because there is a need for dosage adjustment based upon renal function, assessment of renal function is recommended prior to initiation of JANUVIA and periodically thereafter. Creatinine clearance can be estimated from serum creatinine using the Cockcroft-Gault formula. [See Clinical Pharmacology (12.3) .] There have been postmarketing reports of worsening renal function in patients with renal insufficiency, some of whom were prescribed inappropriate doses of sitagliptin.

Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin

When JANUVIA is used in combination with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Sitagliptin in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Sitagliptin in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Safety and effectiveness of JANUVIA in pediatric patients under 18 years of age have not been established.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Sitagliptin in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Sitagliptin in pediatric patients.

Contraindications

Condition1

Warnings

Description

Precautions

Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Sitagliptin in the drug label.

Body as a Whole

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Sitagliptin in the drug label.

Body as a Whole

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Drug Interactions

Drug

Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

Pregnancy Category

Pregnancy Category (AUS):

Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Sitagliptin in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Sitagliptin during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Sitagliptin with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Sitagliptin with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Sitagliptin with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Sitagliptin with respect to specific gender populations.

Race

There is no FDA guidance on the use of Sitagliptin with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Sitagliptin in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Sitagliptin in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Sitagliptin in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Sitagliptin in patients who are immunocompromised.

Administration and Monitoring

Administration

Oral

Intravenous

Monitoring

There is limited information regarding Monitoring of Sitagliptin in the drug label.

Description

IV Compatibility

There is limited information regarding IV Compatibility of Sitagliptin in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

Description

Management

Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Sitagliptin in the drug label.

Pharmacology

There is limited information regarding Sitagliptin Pharmacology in the drug label.

Mechanism of Action

Structure

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Sitagliptin in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Sitagliptin in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Sitagliptin in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Sitagliptin in the drug label.

How Supplied

Storage

There is limited information regarding Sitagliptin Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Sitagliptin |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Sitagliptin |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Sitagliptin in the drug label.

Precautions with Alcohol

Alcohol-Sitagliptin interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Januvia®^[1]

Look-Alike Drug Names

Januvia® — Enjuvia®^[2]
Januvia® — Jantoven®^[2]
Januvia® — Janumet®^[2]
sitaGLIPtin® — SUMAtriptan®^[2]
sitaGLIPtin® — ZOLMitriptan®^[2]

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

↑ "JANUVIA (sitagliptin) tablet, film coated".
↑ ^2.0 ^2.1 ^2.2 ^2.3 ^2.4 "http://www.ismp.org". External link in |title= (help)

{{#subobject:

 |Page Name=Sitagliptin
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Sitagliptin
 |Label Name=Sitagliptin11.png

}}

{{#subobject:

 |Label Page=Sitagliptin
 |Label Name=Sitagliptin11.png

}}

[1] "JANUVIA (sitagliptin) tablet, film coated".

[www.ismp.org-2] 2.0 ^2.1 ^2.2 ^2.3 ^2.4 "http://www.ismp.org". External link in |title= (help)

[1]

[2]

@@ Line 55: / Line 55: @@
 :* For patients with severe renal insufficiency (CrCl less than 30 mL/min, approximately corresponding to serum creatinine levels of greater than 3.0 mg/dL in men and greater than 2.5 mg/dL in women) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of JANUVIA is 25 mg once daily. JANUVIA may be administered without regard to the timing of dialysis.
 :* Because there is a need for dosage adjustment based upon renal function, assessment of renal function is recommended prior to initiation of JANUVIA and periodically thereafter. Creatinine clearance can be estimated from serum creatinine using the Cockcroft-Gault formula. [See Clinical Pharmacology (12.3)	.]	 There have been postmarketing reports of worsening renal function in patients with renal insufficiency, some of whom were prescribed inappropriate doses of sitagliptin.
 * Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin
@@ Line 65: / Line 64: @@
 |offLabelAdultGuideSupport=
-=====Condition1=====
-* Developed by:
-* Class of Recommendation:
-* Strength of Evidence:
-* Dosing Information
-:* Dosage
-=====Condition2=====
 There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
@@ Line 85: / Line 70: @@
 |offLabelAdultNoGuideSupport=
-=====Condition1=====
-* Dosing Information
-:* Dosage
-=====Condition2=====
 There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
@@ Line 102: / Line 79: @@
 |fdaLIADPed=
-=====Condition1=====
+* Safety and effectiveness of JANUVIA in pediatric patients under 18 years of age have not been established.
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 <!--Off-Label Use and Dosage (Pediatric)-->
@@ Line 117: / Line 86: @@
 |offLabelPedGuideSupport=
-=====Condition1=====
-* Developed by:
-* Class of Recommendation:
-* Strength of Evidence:
-* Dosing Information
-:* Dosage
-=====Condition2=====
 There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
@@ Line 137: / Line 92: @@
 |offLabelPedNoGuideSupport=
-=====Condition1=====
-* Dosing Information
-:* Dosage
-=====Condition2=====
 There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.